Look up one drug

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Jamp Sodium Polystyrene Sulfonate · DIN 02497557 Manufacturer: Jamp Pharma Corporation; listing date 2021-08-31 Health Canada: Marketed since 2021-02-04 · brand JAMP SODIUM POLYSTYRENE SULFONATE · ATC V03AE01 POLYSTYRENE SULPHONATE · form Powder for suspension · route Rectal, Oral · ingredients SODIUM POLYSTYRENE SULFONATE 1 G/G · company Jamp pharma corporation · schedule Prescription

DIN 02497557: Jamp Sodium Polystyrene Sulfonate Raw flags: sec3=Y Item: 401800001; group id 551; item number 1487; lccId None; manufacturer id JPC Source form: Oral Pd-454g Pk; strength: 1mEq/g Recorded listing: General benefit Source prices (unrounded): $29.4175; ministry $29.4175 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02497557 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98738

Interchangeable products

Kayexalate · DIN 02026961 · $29.4175 Odan-Sodium Polystyrene Sulfonate · DIN 02473941 · $29.4175 Solystat · DIN 00755338 · $29.4175

Shortage status: active shortage (reported 2026-04-21, estimated to end 2026-10-09, last updated 2026-07-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02497557

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Kayexalate · DIN 02026961 Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01 Health Canada: Marketed since 2009-02-06 · brand KAYEXALATE · ATC V03AE01 POLYSTYRENE SULPHONATE · form Powder for suspension · route Oral, Rectal · ingredients SODIUM POLYSTYRENE SULFONATE 1 G/G · company Sanofi-aventis canada inc · schedule Prescription

DIN 02026961: Kayexalate Raw flags: sec3=Y Item: 401800001; group id 551; item number 1487; lccId None; manufacturer id SAV Source form: Oral Pd-454g Pk; strength: 1mEq/g Recorded listing: General benefit Source prices (unrounded): $43.6300; ministry $29.4175 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02026961 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17752

Interchangeable products

Jamp Sodium Polystyrene Sulfonate · DIN 02497557 · $29.4175 Odan-Sodium Polystyrene Sulfonate · DIN 02473941 · $29.4175 Solystat · DIN 00755338 · $29.4175

Shortage status: resolved shortage (ended 2024-07-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02026961

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Odan-Sodium Polystyrene Sulfonate · DIN 02473941 Manufacturer: Odan Laboratories Ltd.; listing date 2019-05-31 Health Canada: Marketed since 2018-10-25 · brand ODAN-SODIUM POLYSTYRENE SULFONATE · ATC V03AE01 POLYSTYRENE SULPHONATE · form Powder for suspension · route Rectal, Oral · ingredients SODIUM POLYSTYRENE SULFONATE 1 G/G · company Odan laboratoriesltd · schedule Prescription

DIN 02473941: Odan-Sodium Polystyrene Sulfonate Raw flags: sec3=Y Item: 401800001; group id 551; item number 1487; lccId None; manufacturer id ODN Source form: Oral Pd-454g Pk; strength: 1mEq/g Recorded listing: General benefit Source prices (unrounded): $29.4175; ministry $29.4175 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02473941 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96396

Interchangeable products

Jamp Sodium Polystyrene Sulfonate · DIN 02497557 · $29.4175 Kayexalate · DIN 02026961 · $29.4175 Solystat · DIN 00755338 · $29.4175

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02473941

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Solystat · DIN 00755338 Manufacturer: Pendopharm, Division of Pharmascience Inc.; listing date 2021-02-26 Health Canada: Marketed since 2014-01-28 · brand SOLYSTAT · ATC V03AE01 POLYSTYRENE SULPHONATE · form Powder for suspension · route Oral, Rectal · ingredients SODIUM POLYSTYRENE SULFONATE 1 G/G · company Pendopharm division of pharmascience inc · schedule Prescription

DIN 00755338: Solystat Raw flags: sec3=Y Item: 401800001; group id 551; item number 1487; lccId None; manufacturer id PEN Source form: Oral Pd-454g Pk; strength: 1mEq/g Recorded listing: General benefit Source prices (unrounded): $29.4175; ministry $29.4175 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00755338 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8918

Interchangeable products

Jamp Sodium Polystyrene Sulfonate · DIN 02497557 · $29.4175 Kayexalate · DIN 02026961 · $29.4175 Odan-Sodium Polystyrene Sulfonate · DIN 02473941 · $29.4175

Shortage status: resolved shortage (ended 2024-10-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00755338

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Odan-Sodium Polystyrene Sulfonate · DIN 02473968 Manufacturer: Odan Laboratories Ltd.; listing date 2019-07-31 Health Canada: Marketed since 2018-12-11 · brand ODAN-SODIUM POLYSTYRENE SULFONATE · ATC V03AE01 POLYSTYRENE SULPHONATE · form Suspension · route Oral, Rectal · ingredients SODIUM POLYSTYRENE SULFONATE 250 MG/ML · company Odan laboratoriesltd · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02473968). DIN 02473968: Odan-Sodium Polystyrene Sulfonate Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 401800004; group id 551; item number 1486; lccId None; manufacturer id ODN Source form: O/L; strength: 250mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.1954; ministry $0.1954 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02473968 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96397

Interchangeable products

Solystat · DIN 00769541 · not recorded

Shortage status: active shortage (reported 2024-11-01, last updated 2024-11-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02473968

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Solystat · DIN 00769541 Manufacturer: Pendopharm, Division of Pharmascience Inc.; listing date 2019-07-31 Health Canada: Marketed since 2012-06-19 · brand SOLYSTAT · ATC V03AE01 POLYSTYRENE SULPHONATE · form Suspension · route Oral · ingredients SODIUM POLYSTYRENE SULFONATE 250 MG/ML · company Pendopharm division of pharmascience inc · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 00769541). DIN 00769541: Solystat Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 401800004; group id 551; item number 1486; lccId None; manufacturer id PEN Source form: O/L; strength: 250mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00769541 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9611

Interchangeable products

Odan-Sodium Polystyrene Sulfonate · DIN 02473968 · $0.1954

Shortage status: active shortage (reported 2025-12-22, estimated to end 2026-09-28, last updated 2026-08-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00769541

Shortage record checked 2026-09-13T08:10:21.292534+00:00